MedX(R) Announces Positive Results From Low-Level Laser Therapy Study in Wound Healing

    Research results presented at the World Union of Wound Healing Societies
    Congress 2008 in Toronto

    MISSISSAUGA, ON, June 5 /CNW/ - MedX Health Corp. (TSXV: MDX) today
announced the publication of positive results from a study of low-level laser
therapy (LLLT) for healing acute and chronic wounds combined with the
Extendicare Wound Prevention and Management Program. Although the study was
completed a number of years ago, these positive results are just being
presented formally, and for the first time are appearing in the peer-reviewed
journal, International Wound Journal. The nine-week study evaluated the effect
of low-level laser therapy on wound healing in 16 patients at a Canadian
Extendicare nursing home. At the end of the study, 61.9 percent of the wounds
achieved significant improvement ((greater than) 50 percent wound closure) and
42.8 percent had 100 percent closure. None of the wounds deteriorated during
the study and no negative consequences of treatment were encountered. In
addition, a retrospective review of the data revealed an estimated total cost
savings of $220 per month per patient in labor and supplies.
    "We are very pleased with the positive research results of our low-level
laser system in wound care," said Steve Guillen B.Sc., M.B.A., President and
Director, MedX Health. "Pressure ulcers and chronic wounds are a common and
costly problem in nursing home settings. MedX has a long history of offering
innovative laser and light therapy products that have successfully treated
pain, sports injuries and other conditions and we believe our products can
offer patients with acute and chronic wounds a non-invasive, drug free
    Chronic wounds can be painful and debilitating for patients and the care
and management of these wounds can have significant economic consequences. The
study results demonstrate that MedX's low-level laser system was very easy to
learn and use and offered relief for frail and elderly patients who suffered
from acute and chronic wounds.
    The study results indicated similar wound closure rates were achieved for
both chronic and acute wounds, suggesting LLLT may play an important role in
enhancing wound healing regardless of chronicity. In addition, previous
research has demonstrated LLLT increases microcirculation and tensile strength
of new tissue, offering a potential opportunity for LLLT in the preventative
treatment of recently closed wounds that have a history of reopening.
Additionally, MedX LLLT provided sufficient pain control from a lack of blood
flow to the area, to allow a couple of patients in chronic pain to sleep and
participate more in their daily activities. Finally, an anecdotal result of
the study showed increased vigilance and active participation by the health
care workers at the facility who participated in the research due to having a
concrete treatment option for these difficult-to-manage wounds.

    About Low-Level Laser Therapy
    For more than 35 years, LLLT has been used in Europe, Australia, Asia and
Russia for the treatment of pain and tissue repair. LLLT was approved in
Canada in the early 1990's and in the United States in 2002. LLLT uses a
specific type of light to penetrate the skin's surface and underlying tissues
to stimulate the body's natural repair processes. The result is faster healing
and reduced pain, swelling and inflammation.
    The MedX 1000 Console system used in the study has two 80 mW infrared
laser clusters for large area treatment and one 50 mW single diode infrared
laser probe for more focused, deeper applications. The study incorporated LLLT
into the established, standardized Extendicare Wound Prevention and Management

    About MedX Health Corp.

    MedX is a leading North American developer and manufacturer of
phototherapy medical devices, including dental, rehabilitation and wound care
products. MedX plans to use the proceeds from its recent public offering to
expand its distribution network; support its marketing program; continue
development of new dental, rehabilitation and wound care products; undertake
research and development for wound care products; and for working capital
purposes. In particular, MedX plans to accelerate the development of a new
product aimed at the rapidly-growing wound care market: its "Photobandage", a
bandage technology that allows a wound to be bathed in light, designed to
enhance the healing process. The Company intends to license this new
technology to one or more major wound care companies for further development,
marketing and sales.

    The TSX Venture Exchange does not accept responsibility for the adequacy
    or accuracy of this press release.

    This press release contains "forward-looking information" within the
meaning of applicable Canadian securities legislation. Such forward-looking
information may include statements regarding the Company's future plans,
objectives, performance, growth, profits, operating expenses or its underlying
assumptions. Generally, forward-looking information can be identified by the
use of forward-looking terminology such as "plans", "expects", or "does not
expect", "is expected", "budget", "scheduled", "estimates", "forecasts",
"intends", "anticipates", or "does not anticipate", or "believes" or
variations of such words and phrases or state that certain actions, events or
results "may", "could", "would", "might", or "will be taken", "occur", or "be
achieved". Forward-looking information is subject to known and unknown risks,
uncertainties and other factors that may cause the actual results, level of
activity, performance or achievements of MedX to be materially different from
those expressed or implied by such forward-looking information, including
uncertainty of successful development of new products, uncertainty of
successful manufacturing or marketing of products, uncertainty of commercial
acceptance of products, uncertainty concerning governmental regulation,
dependency on key employees and relationships, rapid technological changes,
foreign currency fluctuations. MedX does not undertake to update any
forward-looking information, except in accordance with applicable securities

    %SEDAR: 00017466E

For further information:

For further information: Steve Guillen, President & Director, MedX
Health Corp., Phone: (905) 826-0766, Email:; Nelson
Smith, Taddle Creek Capital, Phone: (416) 565-7518, Email:

Organization Profile

MedX Health Corp.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890